Prior Authorization Delays Heart Failure Drug Access, Exacerbating Disparities
Event summary
- NYU Langone Health researchers found prior authorization significantly delays access to ARNI and SGLT2 inhibitors, critical medications for heart failure.
- Patients requiring prior authorization took three times longer to fill ARNI prescriptions and six times longer for SGLT2 inhibitors, with twice the likelihood of non-fill.
- The study, analyzing data from 2,183 patients between 2021 and 2023, revealed prior authorization disproportionately affects patients in lower socioeconomic areas and those identifying as Black or Hispanic, often with Medicaid insurance.
- The findings suggest prior authorization policies, intended to control costs, may be hindering patient access to guideline-recommended treatments and contributing to health disparities.
The big picture
This study highlights a growing tension between cost containment measures and patient access within the US healthcare system. Prior authorization, while intended to manage pharmaceutical spending, appears to be creating significant barriers to guideline-recommended therapies, particularly for vulnerable populations. The findings underscore the need for a more nuanced approach to value-based care that balances cost efficiency with equitable patient outcomes, and may accelerate the trend of patient advocacy groups challenging restrictive insurance practices.
What we're watching
- Insurance Response
- Payers will likely face pressure to re-evaluate prior authorization protocols for these medications, potentially leading to policy changes or increased administrative burden.
- Clinical Practice
- Clinicians may increasingly push back against prior authorization requirements, potentially impacting physician-insurer relationships and treatment pathways.
- Legislative Action
- The findings could spur legislative or regulatory scrutiny of prior authorization practices, particularly concerning access to essential medications and health equity.
Related topics